Evolving Standards: An Examination of NAPLEX Blueprint Changes and Implications for the Academy

IF 3.8 4区教育学 Q1 EDUCATION, SCIENTIFIC DISCIPLINES

American Journal of Pharmaceutical Education Pub Date : 2025-04-03 DOI:10.1016/j.ajpe.2025.101400

Diana M. Sobieraj , Thomas M. Ellington , Aleda M.H. Chen , Michael P. Kelsch , Lisa Lebovitz , Sarah Spinler , Mary E. Ray

{"title":"Evolving Standards: An Examination of NAPLEX Blueprint Changes and Implications for the Academy","authors":"Diana M. Sobieraj , Thomas M. Ellington , Aleda M.H. Chen , Michael P. Kelsch , Lisa Lebovitz , Sarah Spinler , Mary E. Ray","doi":"10.1016/j.ajpe.2025.101400","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To examine changes in the North American Pharmacist Licensure Examination (NAPLEX) blueprint from 2007 to 2025 and identify trends in the blueprint competencies and their alignment with curricular standards.</div></div><div><h3>Methods</h3><div>Members of the research team created a crosswalk using the 2025 NAPLEX blueprint as the reference year, to which they mapped the 2007, 2016, and 2021 blueprints. The crosswalk was distributed to several other assessment and curriculum colleagues at various institutions, public and private, for iterative review and revision until consensus was reached. The same process was used to map the 2025 blueprint to Curriculum Outcomes and Entrustable Professional Activities 2023.</div></div><div><h3>Results</h3><div>New NAPLEX subdomains in 2025 include immunization, ethics, and mentorship/preceptorship. Notable differences in blueprints include structural changes in content moving from separately identifiable areas (ie, math and compounding) and into a collective domain with other content and reducing formulation-related content while increasing clinical content. The latter aligns with a substantial amount of content mapping to the “provider” and “problem-solver” curricular outcomes and the clinical sciences, particularly, medication use processes, area of Accreditation Council for Pharmacy Education Standards 2025 Appendix 1.</div></div><div><h3>Conclusion</h3><div>The 2025 NAPLEX blueprint resembles a shift toward clinical content in comparison to previous blueprints. Curricular outcomes related to solving problems; providing whole person care; and stewardship of medication systems for prescribing, order processing, dispensing, administration, and effects monitoring align with the new NAPLEX blueprint.</div></div>","PeriodicalId":55530,"journal":{"name":"American Journal of Pharmaceutical Education","volume":"89 5","pages":"Article 101400"},"PeriodicalIF":3.8000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Pharmaceutical Education","FirstCategoryId":"95","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002945925000452","RegionNum":4,"RegionCategory":"教育学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"EDUCATION, SCIENTIFIC DISCIPLINES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To examine changes in the North American Pharmacist Licensure Examination (NAPLEX) blueprint from 2007 to 2025 and identify trends in the blueprint competencies and their alignment with curricular standards.

Methods

Members of the research team created a crosswalk using the 2025 NAPLEX blueprint as the reference year, to which they mapped the 2007, 2016, and 2021 blueprints. The crosswalk was distributed to several other assessment and curriculum colleagues at various institutions, public and private, for iterative review and revision until consensus was reached. The same process was used to map the 2025 blueprint to Curriculum Outcomes and Entrustable Professional Activities 2023.

Results

New NAPLEX subdomains in 2025 include immunization, ethics, and mentorship/preceptorship. Notable differences in blueprints include structural changes in content moving from separately identifiable areas (ie, math and compounding) and into a collective domain with other content and reducing formulation-related content while increasing clinical content. The latter aligns with a substantial amount of content mapping to the “provider” and “problem-solver” curricular outcomes and the clinical sciences, particularly, medication use processes, area of Accreditation Council for Pharmacy Education Standards 2025 Appendix 1.

Conclusion

The 2025 NAPLEX blueprint resembles a shift toward clinical content in comparison to previous blueprints. Curricular outcomes related to solving problems; providing whole person care; and stewardship of medication systems for prescribing, order processing, dispensing, administration, and effects monitoring align with the new NAPLEX blueprint.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Pharmaceutical Education 医学-学科教育

CiteScore

4.30

自引率

15.20%

发文量

114

期刊介绍： The Journal accepts unsolicited manuscripts that have not been published and are not under consideration for publication elsewhere. The Journal only considers material related to pharmaceutical education for publication. Authors must prepare manuscripts to conform to the Journal style (Author Instructions). All manuscripts are subject to peer review and approval by the editor prior to acceptance for publication. Reviewers are assigned by the editor with the advice of the editorial board as needed. Manuscripts are submitted and processed online (Submit a Manuscript) using Editorial Manager, an online manuscript tracking system that facilitates communication between the editorial office, editor, associate editors, reviewers, and authors. After a manuscript is accepted, it is scheduled for publication in an upcoming issue of the Journal. All manuscripts are formatted and copyedited, and returned to the author for review and approval of the changes. Approximately 2 weeks prior to publication, the author receives an electronic proof of the article for final review and approval. Authors are not assessed page charges for publication.